Hydrogen sulfide (H 2 S) therapy protects non-diabetic animals in various models 30 of myocardial injury, including acute myocardial infarction and heart failure. 31
Introduction 52
The endogenously produced gasotransmitter, hydrogen sulfide (H 2 S), exerts 53 cytoprotective effects in various models of cardiac injury. Specifically, treatment 54 with H 2 S before, during or after myocardial ischemia decrease injury (3, 6, 25) . 55
Furthermore, chronic H 2 S therapy improves survival and protects against 56 ischemic-induced heart failure (2). These cytoprotective effects have been 57 attributed to H 2 S' ability to upregulate antioxidant defenses and to reduce 58 apoptosis, inflammation, and mitochondrial injury (22) . Increasing evidence 59
suggests that hyperglycemia-induced ROS production contributes to oxidative 60 stress, resulting in myocardial damage (1). Thus, the reported antioxidant effects 61 of H 2 S may be of critical importance in the diabetic myocardium. H 2 S upregulates 62 endogenous antioxidant defenses by activating nuclear factor E2-related factor 63 (Nrf2), a member of the NF-E2 family of nuclear basic leucine zipper transcription 64 factors (3). Nrf2 regulates the gene expression of a number of enzymes that 65 serve to detoxify pro-oxidative stressors (7), including heme-oxygenase-1 (HO-1) 66 and NADPH;quinine oxidoreductase 1 (NQO1), by binding to the antioxidant 67 response element (ARE) found in the gene's promoter region (30, 38) . 68 H 2 S is produced enzymatically in mammalian species via the action of three 69 enzymes in the cysteine biosynthesis pathway: cystathionine-γ-lyase (CSE), 70 cystathionine-β-synthase (CBS), and 3-mercaptopyruvate sulfurtransferase . Several studies suggest that streptozotocin (STZ)-induced diabetes 72 (model of Type 1 diabetes) increases the expression of CSE and CBS in the 73 pancreas, kidney and liver (36, 37) . In contrast, additional studies found thatSTZ does not alter the expression of either enzyme in the aorta, liver, kidney or 75 heart (4, 27). Despite this contrasting evidence regarding the affects of induced diabetes on the expression of CSE and CBS, there is clear evidence that 77 circulating levels of H 2 S are decreased in animal models of diabetes (12, 27, 37) 78 and may even contribute to the pathophysiology of diabetes (28). More 79 importantly, lower circulating H 2 S levels have been detected in plasma samples 80 taken from patients with T2DM (12, 32) . 81
Recently, therapeutic strategies aimed at increasing the levels of H 2 S have been 82
shown to provide protection against cardiomyopathy and vascular dysfunction in 83 models of STZ-induced diabetes (5, 27). However, it has yet to be determined if it 84 has similar effects in the setting of T2DM. Therefore, the purpose of this study 85 was to investigate the potential cardioprotective effects of H 2 S therapy in the 86 setting of T2DM using a well-established in vivo mouse model of MI/R injury. 
Materials and Methods 95

Animals.
Male non-diabetic (C57BLKS/J) and diabetic (BKS.Cg-96 Dock7 M +/+Lepr with shaking at 125 rpm on a rotary shaker to facilitate the release of H 2 S gas 163 from the aqueous phase. After shaking, 0.1 mL of head-space gas was applied to 164 a gas chromatograph as detailed above. For the measurement of H 2 S and 165 sulfane sulfur in blood, 0.1 mL and 0.05 mL of whole blood was used for each 166 measurement, respectively. The concentrations of H 2 S in the samples were 167 calculated using a standard curve of Na 2 S as a source of H 2 S. Chromatographs 168 were captured and analyzed with Agilent ChemStation software (B.04.03). For 169 tissue, the amount of H 2 S is reported as nmole/mg wet weight. For the blood, 170 the amount of H 2 S is reported as µM. 171
Enzymatic Production of Hydrogen Sulfide. Enzyme reactions to determine 172 the production of H 2 S from 3-MST were performed as described previously (24) . 173
Briefly, heart tissue was homogenized in buffer containing 100 mM potassium 174 phosphate, pH 7.4, 1 mM dithiothreitol (DTT), and protease inhibitor cocktail 175 ''complete''. For enzyme reactions, 0.2 mL of the homogenate was incubated 176 with 0.022 mL of substrate mix (10 mM L-cysteine and 0.5 mM α-ketoglutarate) 177 in a sealed vial at 37°C for 50 minutes. After adding 0.444 ml of 1 M sodium 178 citrate buffer (pH 6.0), the mixtures were incubated at 37°C for 10 min with 179 shaking on a rotary shaker to facilitate a release of H 2 S gas from the aqueous 180 phase. After shaking, 0.1 mL of head-space gas was applied to a gas 181 chromatograph as described above. 182
183
Enzyme reactions to determine the production of H 2 S from CBS and CSE were 184 performed as described previously (37) with slight modification. Briefly, hearttissue was homogenized in buffer containing 100 mM potassium phosphate, pH 186 7.4. For enzyme reactions, 0.172 mL of homogenate was incubated with 0.028 187 mL of substrate mix (10 mM L-cysteine, 2 mM pyridoxal 5′-phosphate) in a 188 sealed vial at 37°C for 30 minutes. After adding 0.400 ml of 1 M sodium citrate 189 buffer (pH 6.0), the mixtures were incubated at 37°C for 10 min with shaking on a 190 rotary shaker to facilitate a release of H 2 S gas from the aqueous phase. After 191 shaking, 0.1 mL of head-space gas was applied to a gas chromatograph as 192 described above. the gene expression of all three enzymes were elevated in the diabetic heart 234 compared to the non-diabetic heart (Fig. 1A) . The protein expression of CBS and 235 CSE were unaltered in the diabetic heart compared to the non-diabetic heart 236 (Fig. 1B) . However, the expression of 3-MST was significantly upregulated 237 (p<0.001 vs. Non-Diabetic). Further studies revealed that the biosynthesis of 238 H 2 S from the pyridoxal-5'-phosphate (PLP)-dependent enzymes, CBS and CSE, 239 as well as from 3-MST was decreased in the diabetic heart ( Fig. 1D; p<0 .05 vs. 240
Non-Diabetic). Finally, free H 2 S and sulfane sulfur levels were significantly lower 241 in the blood and heart of diabetic mice compared to non-diabetic mice ( Fig. 1E-F Given that diabetes is a condition in which preconditioning strategies may have 246 clinical relevance, studies were conducted to determine if Na 2 S therapy could 247 increase sulfide levels and provide protection against acute myocardial I/R injury.
For these studies, diabetic mice received either a single tail vein injection of Na 2 S 249 the day before experimentation (Na 2 S PC; 0.1 mg/kg) or Na 2 S for 7 days prior to 250 experimentation (Na 2 S 7d PC) or Vehicle. Free H 2 S levels were not different 251 between the groups (Fig. 2A) . However, sulfane sulfide levels were slightly 252 higher in the hearts of the Na 2 S PC mice (p=NS) and significantly increased in 253 the hearts of Na 2 S 7d PC mice ( Fig. 2B; p<0 .001 vs. Vehicle and Na 2 S PC). effects between the two therapeutic approaches reveals that the 7-day 263 pretreatment strategy was 51% more effective in reducing INF/AAR than the 264 acute strategy (p<0.05). Likewise, both strategies significantly decreased 265 circulating Troponin-I levels when compared to the Vehicle-treated mice ( Fig. 2E ; 266 p<0.05). These changes were independent of any effects on body weight or 267 blood glucose levels ( Table 1) . 268 269 Na 2 S therapy reduced myocardial I/R-induced oxidative stress and 271
apoptosis. 272
In response to myocardial I/R injury, lipid peroxidation and 8-isoprostane levels 273 increased in all of the groups ( Figure 3A-B) . Lipid peroxidation levels were 274 significantly lower in the Na 2 S PC mice compared to the Vehicle-treated mice 275 (p<0.05). However, both markers of oxidative stress were significantly lower in 276 the Na 2 S 7d PC mice (p<0.001 vs. Vehicle). Furthermore, lipid peroxidation 277 levels were significantly lower in the Na 2 S 7d PC mice compared to the Na 2 S PC 278 mice (p<0.01), whereas 8-isoprostane levels trended lower. MI/R also increased 279 the expression of cleaved caspase-3 in the hearts of all the groups ( Fig. 3C-D ; 280 p<0.001 vs. Sham). The hearts of both groups of mice treated with Na 2 S 281 exhibited a significant reduction in cleaved caspase-3 expression compared to 282
Vehicle-treated mice (p<0.05 for Na 2 S PC and p<0.01 for Na 2 S 7d PC). 283
Additionally, the Na 2 S 7d PC mice displayed a lower expression compared to the 284 Na 2 S PC mice (p<0.05). 285 286 Na 2 S treatment strategies affect the expression of NQO1 and HO-1 287
differently. 288
Experiments were then conducted to elucidate potential mechanisms responsible 289 for the cardioprotective effects of Na 2 S pretreatment. As an initial measure, it was 290 determined if diabetes altered the expression of Nrf2. For these experiments, 291
non-diabetic and db/db diabetic mice were sacrificed at 12 weeks of age. Westernblot analysis revealed no difference in the whole cell or nuclear expression of 293 Nrf2 between non-diabetic and diabetic mice (Fig. 4A) . Next, experiments were 294 conducted to determine if Na 2 S pretreatment induced Nrf2 signaling in the 295 diabetic heart. For these experiments, both the acute and 7 day strategies were 296 investigated. For the acute strategy (Na 2 S Acute), Na 2 S was administered to 297 diabetic mice and heart tissue was collected 1 hour and 24 hours later. One hour 298 after the administration of Na 2 S, the nuclear expression of Nrf2 was increased 299 ( Fig. 4B ; p<0.001 vs. Sham). Analysis at 24 hours revealed that NQO1 levels 300 were significantly increased ( Fig. 4C ; p<0.001 vs. Sham). In contrast, HO-1 301 levels were not increased at this time point. Analysis revealed that the nuclear 302 expression of Nrf2 remained elevated after 7 days treatment (Na 2 S 7d; Fig. 4B ; 303 p<0.001 vs. Sham). Furthermore, NQO1 levels also remained elevated in the 304 hearts of mice treated with Na 2 S for 7 days ( Fig. 4C; p<0 .001 vs. Sham) . 305
Importantly, 7 days of Na 2 S treatment increased HO-1 levels in the hearts of 306 diabetic mice (p<0.05 vs. Sham) . 307
Next, chromatin immunoprecipitation (ChIP) assays were performed to examine 308 the binding of Nrf2 to the ARE in the NQO1 and HO-1 promoters. As shown in 309 
Pretreatment with Na 2 S does not alter the nuclear expression of Keap1 or 316
Fyn in the Diabetic Heart but does reduce the expression of Bach1. 317
In an effort to determine the possible mechanisms underlying the diminished 318 binding of Nrf2 to the ARE in the HO-1 promoter, the expression of 3 proteins 319 known to influence the signaling or activation of Nrf2 were evaluated: Kelch-like 320 ECH-associated protein 1 (Keap1), Fyn, and Bach1. The expression of each was 321 first evaluated in the nuclear fraction of heart tissue taken from non-diabetic and 322 diabetic mice and then evaluated in the nuclear fraction of heart tissue taken 323 from Vehicle, Na 2 S PC and Na 2 S 7d PC treated mice. The nuclear expression 324 of Keap1 was similar in the hearts of non-diabetic and diabetic Sham mice (Fig.  325 5A) and no significant changes were observed in either group of mice treated 326 with Na 2 S (Fig. 5B) . The expression of Fyn kinase, a key regulator of Nrf2 327 nuclear export (11), was then evaluated. The nuclear expression of Fyn was 328 significantly elevated in the hearts of diabetic mice when compared to non-329 diabetic mice ( Fig. 5A; p<0 .001). However, neither pretreatment strategy of Na 2 S 330 altered the nuclear expression of Fyn (Fig. 5B) . Experiments then focused on 331 Bach1, a stress responsive transcription factor that has been reported to repress 332 the transcription of HO-1 by competing with Nrf2 in binding to the promoter of 333 HO-1 (15). As with Fyn, the nuclear expression of Bach1 was significantly 334 elevated in the hearts of diabetic mice compared to non-diabetic mice ( Fig. 5A ; 335 p<0.05). Importantly, the expression of Bach1 trended lower in the Na 2 S PC mice 336 ( Fig. 5B ; p=NS vs. Sham) and was markedly decreased in the hearts of Na 2 S 7d 337 PC (p<0.05 vs. Sham) . Further experiments were then conducted to determine ifthe changes in the nuclear levels of Bach1 were accompanied by a decrease in 339 the binding of Bach1 to the NQO1 and HO-1 promoters (Fig. 5C) . ChIP analysis 340 revealed that significantly less Bach1 was bound to the NQO1 promoter in the 341 hearts of Na 2 S PC and Na 2 S 7d PC (p<0.05 vs. Sham). In contrast, a single 342 administration of Na 2 S did not result in less Bach1 bound to the HO-1 promoter 343 in the diabetic heart. However, after 7 days of Na 2 S treatment, significant 344 decrease was observed (p<0.05 vs. Sham). 345
Pretreatment with Na 2 S for 7 days removed Bach1 from the nucleus by 346 activating Erk. 347
Signaling through Erk has been reported to regulate the nuclear localization of 348 Bach1 (9). Analysis revealed that the expression of phosphorylated Erk was not 349 increased in the hearts of Na 2 S PC treated mice (Fig. 6A) . However, Erk 350 phosphorylation was significantly increased in the hearts of Na 2 S 7d PC mice 351 (p<0.001 vs. Sham and p<0.01 vs. Na 2 S PC). Experiments then focused on the 352 importance of Erk in mediating the Na 2 S-induced removal of Bach1 from the 353 nucleus. Since, the nuclear expression of Bach1 was only significantly decrease 354 in the heart of the Na 2 S 7d PC treated mice, these additional studies only 355 focused on 7 days of pretreatment. For these experiments, mice received 356 vehicle, the Erk1/2 signaling inhibitor U0126 (U0126), or U0126 and Na 2 S 357 (U0126+Na 2 S) for 7 days. In the presence of U0126, Na 2 S pretreatment failed to 358 increase the phosphorylation of Erk (Fig. 6B) . Na 2 S pretreatment did, however, 359 increase the nuclear expression of Nrf2 in the presence of U0126 ( Fig. 6C;  360 p<0.05 vs. Sham and U0126), but failed to reduce the nuclear expression ofBach1 (Fig. 6C) and failed to increase the expressions of NQO1 or HO-1 (Fig.  362   6D) . Additionally, Na 2 S pretreatment failed to provide protection against 363 myocardial I/R injury when administered in the presence of U0126 (Fig. 7) . 364 365 366 Discussion 367 368
Our main findings in this study are (1) Na 2 S therapy attenuates MI/R injury in the 369 setting of T2DM; (2) the activity of the three H 2 S-producing enzymes is 370 decreased in the hearts of db/db mice; (3) Nrf2 signaling induced by Na 2 S is 371 partially impaired in the setting of T2DM by Bach1; (4) Na 2 S therapy for 7 days 372 overcomes this impairment by removing Bach1 from the nucleus in a Erk-373 dependent manner. 374
A main finding of our study relates to the effects of T2DM on the activity and 375 expression of the H 2 S-producing enzymes. Similar to previous reports using 376
Type-1 diabetic models, we found that T2DM increased the gene expression of 377
Cbs and Cth. More importantly, for the first time we report that the gene 378 expression of Mpst was upregulated. While the increase in the gene expression 379 of Cbs and Cth did not result in an increase in protein levels of these two 380 enzymes, we did find that the protein expression of 3-MST was significantly 381 upregulated. This suggests that 3-MST could be regulated differently than the 382 other two enzymes in the setting of T2DM. However, the mechanism(s) behind 383 this regulation remain to be elucidated. We also report here for the first time that 384 T2DM lowers cardiac sulfide levels. Suzuki et al (27) suggest that the elevatedlevels of glucose seen in diabetes may cause tissues to increase their 386 consumption of H 2 S resulting in lower levels. While this postulated mechanism 387 could contribute to the lower circulating and cardiac levels seen in the current 388 study, we provide novel evidence that the enzymatic activity of the pyridoxal-5'-389 phosphate (PLP)-dependent enzymes (CBS and CSE) and 3-MST were 390 decreased in the diabetic heart. Therefore, we suggest that the lower levels of 391 H 2 S seen in the setting of diabetes are caused by the decreased production of 392 endogenous H 2 S and/or the increased tissue consumption of the available H 2 S. 393
Currently, the mechanism(s) by which T2DM alters the expression and activity of 394 the enzymes is unknown. There is evidence that the transcription factor, 395 specificity protein 1 (Sp1) regulates the hyperglycemia-induced upregulation of 396
CSE gene expression in pancreatic β-cells (29). However, it is not known if Sp1 397
regulates the cardiac gene expression of CSE in the setting of 398 diabetes/hyperglycemia or if Sp1 regulates the expression of CBS or 3-MST 399 under any conditions. In regards to enzymatic activity, the activity of 3-MST is 400 inhibited by oxidative stress (21). Additionally, thioredoxin interacts with and 401 regulates the H 2 S-producing activity of 3-MST (20, 21). Recent work also 402 demonstrates that hyperglycemia associated with STZ-induced diabetes 403 increases the susceptibility of the heart to I/R injury by enhancing the nitrative 404 inactivation of thioredoxin (35). Therefore, the oxidative stress associated with 405 T2DM may potentially alter the activity of the enzymes. However, further work is 406 needed to test this hypothesis and to determine if thioredoxin can regulate CBS 407 and CSE in a manner similar to 3-MST.
Another main finding of the current study relates to the cardioprotective effects of 409 H 2 S in the setting of T2DM. H 2 S therapy provides protection against several 410 models of myocardial injury in the setting of Type-1 diabetes by alleviating 411 apoptosis and oxidative stress (5, 8, 27) . In agreement, the current study also 412 found that H 2 S attenuates apoptosis and oxidative stress in the setting of 413 diabetes. More importantly, it provides evidence for the first time that H 2 S therapy 414 reduces myocardial injury in the T2DM heart. This is an important observation 415
given that T2DM encompasses roughly 90% of diabetic patients (13). Our study 416 also highlights the complexity of therapeutic intervention for the diabetic heart 417 following ischemia, as the robust cardioprotective effects of H 2 S that have 418 previously been reported in the non-diabetic state (3) were diminished in the 419 diabetic heart. Finally, our study revealed that the 7 days of treatment 420 significantly increased the levels of sulfane sulfur in the heart suggesting that 421 correcting the diabetes-induced deficit of cardiac H 2 S levels may be responsible 422 for the enhanced protection. Sulfane sulfur or bound sulfur has been suggested 423 to be an important storage pool that regulates the amount of bioavailable free 424 H 2 S (17, 33). Moreover, there is evidence to suggest that free H 2 S is released 425 from bound sources under acidic conditions (19). Therefore, during myocardial 426 ischemia it is likely that bound sulfane sulfur becomes a source of free H 2 S, 427 which can then serve as a signaling molecule to protect the heart against 428 ischemic injury. 429
Another major finding of our study relates to aspects of Nrf2 signaling that were 431 impaired in the diabetic heart. This is based on the findings that the two Na 2 S 432 treatment strategies affected the expression of NQO1 and HO-1 differently. The 433 inability of a single injection of Na 2 S to upregulate the expression of HO-1 is in 434 contrast to our previous findings in the non-diabetic heart (3) and may provide an 435 explanation as to why the 7-day treatment strategy lowers oxidative stress and 436 infarct size more than the acute. Therefore, we can speculate that NQO1 is 437 sufficient to provide the moderate antioxidant observed after the acute treatment 438 of Na 2 S, however both NQO1 and HO-1 are able to provide the robust effects 439 induced by the 7-day treatment. Importantly our study revealed that the 440 impairment in Nrf2 signaling as it relates to the regulation of HO-1 was initially 441 caused by the inability of Nrf2 to bind to the ARE in the promoter of HO-1. This 442 suggests two things: 1) although Nrf2 is present in the nucleus after a single 443 injection of Na 2 S something prevents it from binding to the HO-1 promoter and 2) 444 Na 2 S therapy for 7 days overcomes this impairment. 445
Under basal conditions, Keap1 represses the ability of Nrf2 to induce 446 endogenous antioxidants by binding very tightly to Nrf2, anchoring it in the 447 cytoplasm, and targeting it for ubiquitination and proteasome degradation (31). 448
Upon stimulation, Nrf2 dissociates from Keap1 and translocates to the nucleus 449 (16). H 2 S has recently been shown to sulfhydrate Keap1, which results in the 450 release and translocation of Nrf2 to the nucleus (10, 34). Recent findings also 451 indicate that Keap1 acts as a shuttle protein suggesting that it has a functional 452 role not only in the cytoplasm but also in the nucleus (18, 26) . Therefore, itappears that under certain conditions Keap1 travels into the nucleus, dissociates 454
Nrf2 from the ARE sequence and escorts it out of the nucleus in an effort to turn 455 the Nrf2 signaling pathway off (18). The results of the current study indicate that 456 diabetes does not alter the ability of Na 2 S to disrupt the interaction between 457
Keap1 and Nrf2, as evidenced by the findings Na 2 S therapy increased the 458 nuclear levels of Nrf2. Our analysis also found that nuclear Keap1 levels were 459 not altered in the diabetic heart and that Na 2 S did not alter the expression of 460
Keap1. 461
Although Keap1 is the major regulator of Nrf2 activation, there is evidence 462 indicating multiple levels of Nrf2 regulation. For instance, Bach1 directly 463 competes with Nrf2 in binding to the promoter of ARE-related genes leading to 464 the negative regulation of Nrf2 signaling (14, 15). Our initial analysis found that 465 the nuclear expression of Bach1 was increased in the diabetic heart, suggesting 466 that it may contribute to the impairment of Nrf2 signaling in response to Na 2 S as 467 it related to HO-1. We found that an acute treatment of Na 2 S slightly reduced its 468 nuclear expression, whereas 7 days of Na 2 S treatment significantly reduced the 469 nuclear expression of Bach1. Given that this coincided with increased HO-1 470 expression, it can be suggested that 1) Bach1 potentially causes the disruption of 471 Nrf2/HO-1 signaling in the diabetic heart and 2) removal of Bach1 from the 472 nucleus of the diabetic heart allows for Nrf2 to bind to the ARE in the HO-1 473 promoter. The latter was confirmed by ChIP analysis, which demonstrated that 7 474 days of Na 2 S treatment increased the binding of Nrf2 to the HO-1 promoter while 475 at the same time reducing the binding of Bach1. Interestingly, the acutetreatment of Na 2 S decreased the binding of Bach1 to the NQO1 promoter. This 477 provides an explanation as to why NQO1 was increased after the acute 478 treatment and suggests that the binding of Bach1 to the promoter of distinct Nrf2 479 target genes is differently regulated. It also suggests that in the heart binding of 480 Bach1 to the NQO1 promoter is not as tightly regulated as binding to the HO-1 481 promoter. Additionally, inhibition of Erk1/2 signaling prevented Na 2 S therapy from 482 removing Bach1 form the nucleus and subsequently prevented Na 2 S therapy 483 from increasing the expression of NQO1 and HO-1. Inhibition of Erk1/2 signaling 484 also prevented Na 2 S therapy from reducing myocardial injury following I/R, 485
indicating that Erk1/2-mediated activation of Nrf2 signaling in part contributes to 486 the cardioprotective effects of Na 2 S in the db/db diabetic heart. Currently, it is not 487 known how H 2 S increases the phosphorylation of Erk. Previous studies suggest 488 that it could be dependent on PKC (3). Alternatively, H 2 S could phosphorylate Erk 489 in an PKC-independent manner. Therefore, further work is needed to determine 490 the mechanisms by which H 2 S activates both Nrf2 and Erk signaling in the heart. 491
In summary, our findings demonstrate for the first time that T2DM decreases the 492 levels of H 2 S in the heart and that exogenous administrations of Na 2 S attenuate 493 MI/R injury in the setting of T2DM. Our results also provide important insights into 494 the mechanism responsible for this cardioprotection. Specifically, Na 2 S treatment 495 sets into motion events such as Erk phosphorylation, which ultimately lead to the 496 removal of Bach1 from the nucleus and activation of Nrf2 signaling (Fig. 7C) . 497
Finally, given that H 2 S plays multiple protective roles in both the vasculature and 498 the heart, it can be suggested that lower circulating and tissue H 2 S levels maycontribute to the pathophysiology of diabetes (28) 
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